In this article, the author discusses his experiences with failure in medicine. He also describes how what he has learned influences his practices today as a radiation oncology resident.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.